RecruitingPhase 2NCT06925724

A Study of Ivonescimab in People With Endometrial and Cervical Cancers

A Phase 2 Study of Ivonescimab (Bispecific Antibody Against PD1 and VEGF) For the Treatment of Endometrial (EC) and Cervical (CC) Cancers

Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

50 participants

Start Date

Apr 4, 2025

Study Type

INTERVENTIONAL

Conditions

Cervical Cancer Endometrial Cancer

Summary

The researchers are doing this study to find out if ivonescimab is an effective treatment for people with endometrial cancer (EC) and/or cervical cancer (CC). The researchers will also look at whether the study drug is safe and causes few or mild side effects in participants.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing ivonescimab — a new drug that combines immunotherapy (checkpoint inhibitor) and anti-angiogenic therapy (blocking blood supply to tumours) in a single molecule — in patients with advanced endometrial cancer or cervical cancer that has come back after previous treatment. **You may be eligible if...** - You have metastatic or recurrent endometrial cancer or cervical cancer confirmed by biopsy - Your cancer progressed after at least one platinum-based chemotherapy regimen - Your cancer can be measured on imaging scans - Your general health is good to moderate (ECOG score 0–2) - Your blood pressure is adequately controlled **You may NOT be eligible if...** - You have not received any prior platinum-based chemotherapy - You have uncontrolled high blood pressure or significant cardiovascular disease - You are pregnant or breastfeeding - You have active autoimmune disease requiring ongoing treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIvonescimab

Ivonescimab will be administered as 20 mg/kg IV (a fixed dose of 3200 mg for ivonescimab should be used for patients ≥ 160 kg), Q3W administered for 60 minutes (± 10 minutes)